Dose banding of chemotherapy doses at the Juravinski Cancer Centre

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6099-6099 ◽  
Author(s):  
H. W. Hirte ◽  
S. Kagoma ◽  
L. Zhong ◽  
I. Collins ◽  
D. Burns ◽  
...  
Keyword(s):  
Standard Dose ◽  
Waiting Times ◽  
Wait Time ◽  
Phase Iii ◽  
Time Study ◽  
Post Dose ◽  
Drug Dispensing ◽  
Average Patient ◽  
Patient Wait Time ◽  
Selection Of

6099 Background: As the number and complexity of chemotherapy regimens increase, the demands on pharmacy services to reduce chemotherapy preparation and checking times continues to increase. Dose banding, a system whereby doses of intravenous cytotoxic drugs calculated on an individual basis are rounded up or down to predetermined standard doses (the maximum variation of the adjustment between standard dose and doses constituting each band is 5% or less) was identified as a strategy that could be used to address some of the issues around time pressures to help reduce patient waiting times for treatment. Methods: The project consisted of 3 phases; Phase I - literature review to identify dose banding publications; Phase II - selection of drugs to be banded for the pilot. The two drugs selected were 5FU and leukovorin, and Phase III - Time studies pre-, interim and post dose banding implementation to determine drug dispensing time and patients’ wait time for pharmacy related procedures. This occurred for a 2 week period (10 working days) either prior to implementation (pre- 819 patients studied), 4 days after implementation (interim - 854 patients studied) and 4 weeks after implementation (post - 785 patients studied). Results: Drug dispensing time did not decrease with dose banding (pre- 7.9 min, interim - 7.6 min and post - 9.4 min). However, the average patient wait time decreased after piloting the dose banding project (pre - 31.6 min, interim 23.7 min, and post - 27.8 min). The percentage of doses that were banded were 37.8% in the interim time study and 58.2% in the post time study. Conclusions: Although dose banding did not reduce dispensing time in this study, likely because the preparation for dispensing 5FU and leukovorin syringes is normally very simple and quick, patient’s wait time for pharmacy related procedures did decrease. This was probably due to contributions of other factors in the pharmacy process. A reduction in dispensing time could likely be achieved if more complex regimens were considered for dose banding. Dose banding could be used to increase capacity within the chemotherapy suite on the day of administration. It also allows for a better work schedule and increases efficiencies within the chemotherapy preparation and administration areas. (Sponsored by funds from Cancer Care Ontario) No significant financial relationships to disclose.

scholarly journals National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers

2019 ◽  
Vol 15 (5) ◽  
pp. e458-e466 ◽  
Author(s):  
Jessica M. Sugalski ◽  
Timothy Kubal ◽  
Daniel L. Mulkerin ◽  
Rebecca L. Caires ◽  
Penny J. Moore ◽  
...  
Keyword(s):  
National Comprehensive Cancer Network ◽  
Patient Flow ◽  
Wait Time ◽  
Cancer Centers ◽  
Administration Routes ◽  
Chemotherapy Drugs ◽  
Average Patient ◽  
Patient Wait Time ◽  
Standard Practices ◽  
Cancer Network

PURPOSE: The National Comprehensive Cancer Network (NCCN) formed an Infusion Efficiency Workgroup to determine best practices for operating efficient and effective infusion centers. METHODS: The Workgroup conducted three surveys that were distributed to NCCN member institutions regarding average patient wait time, chemotherapy premixing practices, infusion chair use, and premedication protocols. To assess chair use, the Workgroup identified and defined five components of chair time. RESULTS: The average patient wait time in infusion centers ranged from 25 to 102 minutes (n = 23; mean, 58 minutes). Five of 26 cancer centers (19%) routinely mix chemotherapy drugs before patient arrival for patients meeting specified criteria. Total planned chair time for subsequent doses of the same drug regimens for the same diseases varied greatly among centers, as follows: Administration of doxorubicin and cyclophosphamide ranged from 85 to 240 minutes (n = 22); of FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplation) ranged from 270 to 420 minutes (n = 22); of rituximab ranged from 120 to 350 minutes (n = 21); of paclitaxel plus carboplatin ranged from 255 to 380 minutes (n = 21); and of zoledronic acid ranged from 30 to 150 minutes (n = 22) for planned total chair time. Cancer centers were found to use different premedication regimens with varying administration routes that ranged in administration times from zero to 60 minutes. CONCLUSION: There is a high degree of variation among cancer centers in regard to planned chair time for the same chemotherapy regimens, providing opportunities for improved efficiency, increased revenue, and more standardization across centers. The NCCN Workgroup demonstrates potential revenue impact and provides recommendations for cancer centers to move toward more efficient and more standard practices.

scholarly journals Robotic Pharmacy Implementation and Outcomes in Saudi Arabia. A Twenty-One Month Review. (Preprint)

2021 ◽  
Author(s):  
James Waterson ◽  
Hisham Momattin ◽  
Shokry Arafa ◽  
Shahad Momattin ◽  
Rayan Rahal
Keyword(s):  
Saudi Arabia ◽  
Patient Satisfaction ◽  
Waiting Time ◽  
Waiting Times ◽  
Wait Time ◽  
Pharmacy Services ◽  
Patient Wait Time ◽  
Implementation Data ◽  
Dispensing Error ◽  
Dispensing Errors

BACKGROUND We describe the introduction, use and evaluation of an automation and integration pharmacy development program in a private facility in Saudi Arabia. The project was undertaken to meet specific challenges of increasing throughput, reducing medication dispensing error, increasing patient satisfaction, and freeing up pharmacists’ time for increased face-to-face consultations with patients. OBJECTIVE To reduce outpatient waiting times for dispensing of medications, to help to free up time to meet patient expectations for pharmacy services including medication education, to reduce the volume of non-value-added pharmacist tasks, to reduce dispensing error rates, and to aid with the rapid development of a reputation in the served community for patient-centred care for a new facility. METHODS Pre-implementation data for patient wait-time for dispensing of prescribed medications as one measure of patient satisfaction, pharmacist activity and productivity in terms of patient interaction time were gathered. Reported and discovered dispensing errors per 1,000 prescriptions were also aggregated. All pre-implementation data was gathered over an eleven- month period. Initial project goals were set as a 50% reduction in the average patient wait-time, a 15% increase in patient satisfaction regarding pharmacy waiting time and pharmacy services, a 25% increase in pharmacist productivity and zero dispensing errors. This was expected to be achieved within ten months of go-live. RESULTS From go-live, data was gathered on the above metrics in one-month increments. At the 10-month point there had been a 53% reduction in the average waiting time, a 20% increase in patient satisfaction regarding pharmacy waiting time, with a 22% increase in overall patient satisfaction regarding pharmacy services, and a 33% increase in pharmacist productivity. There was a zero-rate dispensing error reported. CONCLUSIONS The robotic pharmacy solution studied was highly effective, but upstream supply chain is vital to throughput maintenance, particularly when automated filling is planned. The automation solution must also be seamlessly and completely integrated into the facility’s software systems for appointments, medication records and prescription in order to garner its full benefits. Patient overall satisfaction with pharmacy services is strongly influenced by waiting time and follow up studies ae required to identify how to use this positive effect and how to optimally use ‘freed-up’ pharmacist time. The extra time spent with patients by pharmacists, and the complete overview of the patient’s medication history, that full integration gives, creates opportunities for tackling challenging issues such as medication nonadherence. Reduced waiting times may also allow for smaller prescription fill volumes, and more frequent outpatient department visits, allowing increased contact time with pharmacists.

scholarly journals Behind the clock: elucidating factors contributing to longer clinic appointment duration and patient wait time

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Daniel Jonathan Kagedan ◽  
Stephen B. Edge ◽  
Kazuaki Takabe
Keyword(s):  
Wait Time ◽  
High Volume ◽  
Advanced Practice ◽  
Single Institution ◽  
Clinic Appointment ◽  
Nurse Assessment ◽  
Patient Wait Time ◽  
Encounter Time ◽  
Examination Room

Abstract Background Longer wait time in ambulatory clinics can disrupt schedules and decrease satisfaction. We investigated factors associated with patient wait time (WT, check-in to examination room placement), approximate clinician time (ACT, completion of nurse assessment to check-out), and total appointment length (TAL, check-in to check-out). Methods A single-institution retrospective study was conducted of breast surgery clinic patients, 2017–2019, using actual encounter times. A before/after analysis compared a five-day 8 hour/day (from a four-day 10 hour/day) advanced practice provider (APP) work-week. Non-parametric tests were used, and medians with interquartile ranges (IQRs) reported. Results 15,265 encounters were identified. Overall WT was 15.0 minutes (IQR:6.0–32.0), ACT 49.0 minutes (IQR:31.0–79.0) and TAL 84.0 minutes (IQR:57.0-124.0). Trainees were associated with 30.0 minutes longer ACT (p < 0.0001); this increased time was greatest for follow-up appointments, least for new patients. Patients arriving > 5 minutes late (versus on-time) experienced shorter WT (11.0 vs. 15.0 minutes, p < 0.0001) and ACT (43.0 vs. 53.0 minutes, p < 0.0001). Busier days (higher encounter volume:APP ratios) demonstrated increased encounter times. After transitioning to a five-day APP work-week, ACT decreased. Conclusions High-volume clinics and trainee involvement prolong ambulatory encounters. Increasing APP assistance, altering work schedules, and assigning follow-up appointments to non-trainees may decrease encounter time.

scholarly journals Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

2020 ◽  
Vol 23 (9) ◽  
pp. 549-558
Author(s):  
Ziad Saad ◽  
Derrek Hibar ◽  
Maggie Fedgchin ◽  
Vanina Popova ◽  
Maura L Furey ◽  
...  
Keyword(s):  
Single Nucleotide Polymorphism ◽  
Nasal Spray ◽  
Phase Iii ◽  
Depression Symptoms ◽  
Antidepressant Response ◽  
Nucleotide Polymorphism ◽  
Post Dose ◽  
Single Nucleotide ◽  
Madrs Score ◽  
Genotype Effect

Abstract Background At ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a MOR antagonist, blocks the antidepressant action of ketamine. We examined drug-induced or endogenous MOR involvement in the antidepressant and dissociative responses to esketamine by assessing the effects of a functional single nucleotide polymorphism rs1799971 (A118G) of OPRM1, which is known to alter MOR agonist-mediated responses. Methods Participants with treatment-resistant depression from 2 phase III, double-blind, controlled trials of esketamine (or placebo) nasal spray plus an oral antidepressant were genotyped for rs1799971. Participants received the experimental agents twice weekly for 4 weeks. Antidepressant responses were rated using the change in Montgomery–Åsberg Depression Rating Scale (MADRS) score on days 2 and 28 post-dose initiation, and dissociative side effects were assessed using the Clinician-Administered Dissociative-States Scale at 40 minutes post-dose on days 1 and 25. Results In the esketamine + antidepressant arm, no significant genotype effect of single nucleotide polymorphism rs1799971 (A118G) on MADRS score reductions was detected on either day 2 or 28. By contrast, in the antidepressant + placebo arm, there was a significant genotype effect on MADRS score reductions on day 2 and a nonsignificant trend on day 28 towards an improvement in depression symptoms in G-allele carriers. No significant genotype effects on dissociative responses were detected. Conclusions Variation in rs1799971 (A118G) did not affect the antidepressant response to esketamine + antidepressant. Antidepressant response to antidepressant + placebo was increased in G-allele carriers, compatible with previous reports that release of endorphins/enkephalins may play a role in mediating placebo effect. Trial Registration NCT02417064 and NCT02418585; www.clinicaltrials.gov

scholarly journals Online Ratings of Primary Care Physicians: Comparison of Gender, Training, and Specialty

2021 ◽  
Vol 8 ◽  
pp. 237437352110077
Author(s):  
Daliah Wachs ◽  
Victoria Lorah ◽  
Allison Boynton ◽  
Amanda Hertzler ◽  
Brandon Nichols ◽  
...  
Keyword(s):  
Primary Care ◽  
Primary Care Physicians ◽  
Waiting Times ◽  
Wait Time ◽  
Primary Care Providers ◽  
Wait Times ◽  
Care Providers ◽  
Female Physicians ◽  
Online Ratings ◽  
And Gender

The purpose of this study was to explore patient perceptions of primary care providers and their offices relative to their physician’s philosophy (medical degree [MD] vs doctorate in osteopathic medicine [DO]), specialty (internal medicine vs family medicine), US region, and gender (male vs female). Using the Healthgrades website, the average satisfaction rating for the physician, office parameters, and wait time were collected and analyzed for 1267 physicians. We found female doctors tended to have lower ratings in the Midwest, and staff friendliness of female physicians were rated lower in the northwest. In the northeast, male and female MDs were rated more highly than DOs. Wait times varied regionally, with northeast and northwest regions having the shortest wait times. Overall satisfaction was generally high for most physicians. Regional differences in perception of a physician based on gender or degree may have roots in local culture, including proximity to a DO school, comfort with female physicians, and expectations for waiting times.

scholarly journals Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis

2018 ◽  
Vol 62 (12) ◽  
Author(s):  
S. Dian ◽  
V. Yunivita ◽  
A. R. Ganiem ◽  
T. Pramaesya ◽  
L. Chaidir ◽  
...  
Keyword(s):  
Adverse Events ◽  
Phase Ii ◽  
Tuberculous Meningitis ◽  
Standard Dose ◽  
Geometric Mean ◽  
Phase Iii ◽  
High Dose ◽  
Treatment Area ◽  
Double Blind ◽  
Time Curve

ABSTRACT High doses of rifampin may help patients with tuberculous meningitis (TBM) to survive. Pharmacokinetic pharmacodynamic evaluations suggested that rifampin doses higher than 13 mg/kg given intravenously or 20 mg/kg given orally (as previously studied) are warranted to maximize treatment response. In a double-blind, randomized, placebo-controlled phase II trial, we assigned 60 adult TBM patients in Bandung, Indonesia, to standard 450 mg, 900 mg, or 1,350 mg (10, 20, and 30 mg/kg) oral rifampin combined with other TB drugs for 30 days. The endpoints included pharmacokinetic measures, adverse events, and survival. A double and triple dose of oral rifampin led to 3- and 5-fold higher geometric mean total exposures in plasma in the critical early days (2 ± 1) of treatment (area under the concentration-time curve from 0 to 24 h [AUC0–24], 53.5 mg · h/liter versus 170.6 mg · h/liter and 293.5 mg · h/liter, respectively; P < 0.001), with proportional increases in cerebrospinal fluid (CSF) concentrations and without an increase in the incidence of grade 3 or 4 adverse events. The 6-month mortality was 7/20 (35%), 9/20 (45%), and 3/20 (15%) in the 10-, 20-, and 30-mg/kg groups, respectively (P = 0.12). A tripling of the standard dose caused a large increase in rifampin exposure in plasma and CSF and was safe. The survival benefit with this dose should now be evaluated in a larger phase III clinical trial. (This study has been registered at ClinicalTrials.gov under identifier NCT02169882.)

scholarly journals An Audit of Wait Times for Service Offered by the Gynaecology Oncology Unit at the University Hospital in Jamaica: Are We Meeting the Standards?

2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 74s-74s
Author(s):  
Ian Bambury ◽  
Christopher Fletcher ◽  
Carole Rattray ◽  
Matthew Taylor ◽  
Charmaine Mitchell ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Conflicts Of Interest ◽  
Waiting Times ◽  
Wait Time ◽  
International Standards ◽  
University Hospital ◽  
Wait Times ◽  
Oncology Unit ◽  
The University ◽  
Mean Time

Abstract 53 Background: The European Board and College of Obstetrics and Gynaecology recommends that time from referral of suspected or proven gynaecological cancers to consultation should be within two weeks and that initiation of treatment should occur within six weeks. It is has been shown that a delay in waiting times beyond these international standards results in significantly increased morbidity and mortality. Methods: An audit of wait times was performed for all patients who presented to the gynaecology oncology unit at the University Hospital in Jamaica for consultation between January 1, 2013 and December 31, 2013. Wait time for consultation was calculated as the date of first referral to the date of initial consultation. Wait time for treatment was calculated as time from consultation to either surgery or initiation of radiation therapy or chemotherapy. Primary site, stage, and the region from which the referrals came were abstracted from the medical record. Results: A total of 1,289 unique patients were seen at least once during the audit period; of these, 108 were new consultations and 1,219 were patients seen for follow-up. 72% were from the greater metropolitan area (Kingston & St. Andrew), while the others were from the surrounding parishes of Jamaica. Of the 108 new patients, malignancy was confirmed in 70 (65%). Case make-up included 23 cases of endometrial cancer (33%); 20 cases of cervical cancer (29%); 16 cases of ovarian cancer (23%); and 11 cases of other gynecologic cancers (vulvar, vaginal, choriocarcinoma) (15%). At presentation, there were 23 patients with stage 1 disease (33%), 16 patients with stage 2 disease (23%), 27 patients with stage 3 disease (38%); and 4 patients with stage 4 disease (6%). 39 out of 70 patients with malignancy (56%) underwent surgery; 11 (15.7%) were treated with radiation therapy; and 22 (31%) were treated with chemotherapy. Among patients with a cancer diagnosis, the mean time from referral to consultation was 2.1 weeks. Mean time from consultation to surgery was 7.6 weeks; mean time from consultation to start of radiotherapy was 16 weeks; and mean time from consultation to start of chemotherapy was 11.6 weeks. 66% of patients underwent surgery within the international standard of six weeks from referral. Only 36% initiated radiation therapy and 14% initiated chemotherapy within six weeks from referral. Conclusion: While the majority of patients met international standards for time to consultation to surgery, wait times for initiation of radiation and chemotherapy were sub-standard. This audit has provided information that will help us to assess the inadequacy of available services and could potentially inform national cancer policies in Jamaica. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

Sign in / Sign up

Export Citation Format

Share Document